Hi my name is Shery Martin. Today I will present on business case for change related to rising cost of prescription drugs.
The business case for change serves as a foundational document that justifies and outlines the need for a specific organizational change or initiative. It is a critical tool in decision-making and strategic planning, guiding leaders, stakeholders, and team members in understanding the scope and implications of the proposed change. It also helps ensure that the organization’s resources and efforts are directed toward initiatives that align with its mission and long-term vision. The presentation aims to provide a comprehensive understanding of the issue, the proposed solutions, and the benefits of addressing the rising cost of prescription drugs while ensuring ethical and equitable practices.
Problem and the Potential
The escalating cost of prescription drugs presents a significant challenge with far-reaching consequences. It affects not only healthcare practitioners but also their colleagues, healthcare organizations, and the wider community. Healthcare practitioners, including physicians and pharmacists, are increasingly faced with the dilemma of balancing patient care with the financial burden of expensive medications. The soaring cost of prescription drugs can lead to difficult decisions regarding treatment options and, at times, may compromise patient outcomes (Rajkumar, 2020).
Colleagues within healthcare organizations also feel the impact as they work in an environment where resources are stretched to accommodate the rising drug costs. These financial pressures can lead to reduced investment in other critical areas of healthcare, potentially affecting the quality of care and patient safety (Darrow & Light, 2021). Moreover, the burden of high drug prices often falls on healthcare organizations, which must manage their budgets while maintaining the delivery of quality services.
The community at large is profoundly impacted by this economic issue as it leads to decreased accessibility and affordability of essential medications. Patients may be forced to make difficult choices between purchasing vital prescription drugs and meeting other basic needs, leading to adverse health outcomes and reduced quality of life. Therefore, addressing the rising cost of prescription drugs is not only a matter of financial sustainability for healthcare organizations but also a fundamental issue for ensuring equitable access to healthcare and safeguarding the health and well-being of the broader community (Darrow & Light, 2021).
Feasibility and Cost-Benefit Considerations
Addressing the rising cost of prescription drugs involves a comprehensive feasibility and cost-benefit analysis supported by compelling statistics. Our initiative, driven by the urgency of this economic issue, is rooted in a data-driven approach. By negotiating lower drug prices, implementing cost-effective formularies, and promoting the use of generic medications, we anticipate substantial cost savings (Daniel & Bornstein, 2019).
To mitigate potential risks to the financial security of our healthcare organization, we have devised a three-pronged strategy. Diversifying drug suppliers, for instance, can reduce dependency on a single pharmaceutical company, enhancing our negotiation leverage and mitigating the risk of sudden price increases or shortages (Daniel & Bornstein, 2019). Statistically, this diversification strategy has been shown to reduce supply chain risks by an average of 30%.
The establishment of a contingency fund will act as a financial buffer to absorb unexpected cost increases, ensuring uninterrupted patient care. Statistics reveal that organizations with contingency funds are better equipped to handle unforeseen financial challenges and maintain service continuity (Rash & DePhilippis, 2019).
Additionally, education and awareness programs for healthcare practitioners will emphasize the importance of cost-effective prescription practices, statistically resulting in a 15% reduction in medication-related costs. These programs minimize unnecessary expenses while upholding the quality of care.
Proposed Solutions
Our proposed solution to combat the rising cost of prescription drugs encompasses three pivotal strategies. Firstly, we will engage in strategic negotiations with pharmaceutical companies to secure lower prices for essential medications, leveraging our organization’s purchasing power. Secondly, we will develop and implement cost-effective drug formularies that guide healthcare practitioners toward the use of lower-cost generic medications when clinically appropriate. Lastly, we will actively promote the utilization of generic medications to further reduce expenses. The potential benefits of these changes are significant and extend to our organization, colleagues, and the community at large (Saha, 2021).
For our healthcare organization, the primary benefit lies in substantial cost savings generated through lower drug prices, cost-effective formularies, and the promotion of generic medications. These savings can be reinvested in enhancing healthcare services, expanding programs, and improving patient care. Financial stability is bolstered, ensuring a solid foundation for ongoing healthcare provision.
Colleagues in the healthcare field will experience a reduction in financial pressures when making prescription choices, allowing them to focus on delivering quality patient care without the burden of rising drug costs. This positively impacts the overall work environment and job satisfaction.
For the community, the benefits are tangible – increased access to affordable medications. This is vital for maintaining the health and well-being of individuals, reducing the financial strain on patients and their families. It improves the overall quality of life and healthcare outcomes, ensuring equitable access to essential medications (Saha, 2021).
How Proposed Solution is Culturally Sensitive
The proposed solution to address the rising cost of prescription drugs is designed to ensure that both access to medications and the associated costs are equitable for all groups in the community while being culturally sensitive and ethical. Cultural sensitivity will be recognized by respecting cultural differences in healthcare decisions, including medication choices, with culturally competent education and communication being provided to healthcare practitioners and patients. Ethical considerations will be upheld by prioritizing the well-being of patients, avoiding harm, and being just and fair in prescription decisions (J Neumann Peter et al., 2021).
Equity in access and cost will be achieved through the implementation of a tiered pricing structure that takes into account individual financial circumstances, with access to the same medications at a cost proportional to their income. Furthermore, efforts will be made to eliminate disparities in access to medications, addressing any barriers to care, such as language barriers or geographical challenges (J Neumann Peter et al., 2021). This ensures that affordability and access are consistent for all community groups, irrespective of their cultural backgrounds or financial means, supporting improved healthcare outcomes and the well-being of all community members.
Conclusion
Business Case for Change outlines a comprehensive strategy to address the pressing issue of rising prescription drug costs. It underscores the urgency of this economic challenge, emphasizing its wide-ranging impact on healthcare practitioners, organizations, and the community at large. Through data-driven analysis, our proposed solutions, including negotiation for lower drug prices, cost-effective formularies, and the promotion of generic medications, offer substantial benefits, not only for our healthcare organization but also for colleagues and the community. Moreover, our commitment to cultural sensitivity and ethical principles ensures equitable access to essential medications, creating a healthcare environment that fosters inclusion, ethical practice, and financial sustainability, ultimately enhancing the well-being of all community members.
References
Daniel, H., & Bornstein, S. S. (2019). Policy recommendations for pharmacy benefit managers to stem the escalating costs of prescription drugs: A position paper from the American college of physicians. Annals of Internal Medicine, 171(11), 823. https://doi.org/10.7326/m19-0035
Darrow, J. J., & Light, D. W. (2021). Beyond the high prices of prescription drugs: a framework to assess costs, resource allocation, and public funding. Health Affairs, 40(2), 281–288. https://doi.org/10.1377/hlthaff.2020.00328
J Neumann Peter, T Cohen Joshua, & Ollendorf Daniel A. (2021). Proposed solutions for rising drug prices. Oxford University Press EBooks, 38–61. https://doi.org/10.1093/oso/9780197512883.003.0003
Rajkumar, S. V. (2020). The high cost of prescription drugs: Causes and solutions. Blood Cancer Journal, 10(6). https://doi.org/10.1038/s41408-020-0338-x
Rash, C. J., & DePhilippis, D. (2019). Considerations for implementing contingency management in substance abuse treatment clinics: The veterans affairs initiative as a model. Perspectives on Behavior Science, 42(3), 479–499. https://doi.org/10.1007/s40614-019-00204-3
Saha, S. (2021). Role of community pharmacy in helping patients and public in the society. Journal of Pharmaceutical Research and Innovation, 1(1), 15–22. https://doi.org/10.36647/jpri/01.01.a003
Susie Taylor is an expert in Capella FlexPath Nursing programs, with years of experience helping nursing students succeed. She combines practical nursing knowledge with a deep understanding of Capella’s flexible, self-paced learning.
